CD28 + CD8-和CD4 + CD25high调节性T细胞在乙型肝炎病毒感染进展过

StephenW

Viral Immunol. 2018 Aug 17. doi: 10.1089/vim.2018.0035. [Epub ahead of print]
Discrepant Clinical Significance of CD28+CD8- and CD4+CD25high Regulatory T Cells During the Progression of Hepatitis B Virus Infection.
Shen XH1,2, Xu P2, Yu X1,3, Song HF2, Chen H2, Zhang XG4,5,6, Wu MY2, Wang XF1,5,6.
Author information

1
    1 Department of Biochemistry and Molecular Biology, School of Biology and Basic Medical Sciences, Soochow University , Suzhou, China .
2
    2 The Affiliated Infectious Hospital of Soochow University , Suzhou, China .
3
    3 Suzhou Science and Technology Town Hospital , Suzhou, China .
4
    4 Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University , Suzhou, China .
5
    5 Jiangsu Key Laboratory of Clinical Immunology, Soochow University , Suzhou, China .
6
    6 Jiangsu Key Laboratory of Gastrointestinal Tumor Immunology, The First Affiliated Hospital of Soochow University , Suzhou, China .

Abstract

Accumulating evidence demonstrates that CD8+CD28- regulatory T cells increase in chronic viral infection as well as tumorigenesis. However, it is still not clear about their characteristics in hepatitis B virus (HBV) infection. In addition, it is not understood whether this regulatory immune subset is distinct from CD4+CD25high regulatory T cells in the aspect of impact on or relationship to the progression of HBV infection. Hence, we investigated their dynamics and compared their correlations with clinical parameters in the chronic and advanced phases of HBV infection. The data showed that compared with healthy controls, the frequencies of CD28+CD8- and CD4+CD25high T cells increased in both chronic and advanced phases, while there is no significant difference between the two case groups. Interestingly, we found that in chronic phase, the frequency of CD8+CD28- subset was negatively correlated with the levels of alanine aminotransaminase (ALT) and aspartate aminotransferase (AST), respectively, and did not present association with HBV DNA load, whereas that of CD4+CD25high T cells was positively correlated with HBV DNA load and the levels of ALT and AST, respectively. Amazingly, in advanced phase, the frequency of CD4+CD25high T cells was negatively correlated with HBV DNA load and the levels of ALT, respectively, while there is no significant correlation between the frequency of CD8+CD28- subset and those clinical parameters. Thereby, our findings demonstrated that CD28+CD8- and CD4+CD25high regulatory T cells might exert distinct effect on modulating antiviral immune responses and mitigate immunomediated liver damage in different phases of HBV infection, which represent potential prognostic markers and therapeutic targets for HBV-infected patients based on further exploration of detailed mechanism.
KEYWORDS:

CD28+CD8− regulatory T cells; CD4+CD25high regulatory T cells; hepatitis B virus infection; liver damage

PMID:
    30117787
DOI:
    10.1089/vim.2018.0035

StephenW

病毒免疫。 2018年8月17日doi：10.1089 / vim.2018.0035。 [提前打印]
CD28 + CD8-和CD4 + CD25high调节性T细胞在乙型肝炎病毒感染进展过程中的临床意义差异。
沉XH1,2，徐P2，余X1,3，宋HF2，陈H2，张XG4,5,6，吴MY2，王XF1,5,6。
作者信息

1
    1苏州大学生物与基础医学院生物化学与分子生物学系，苏州
2
    2苏州大学附属传染病医院，中国苏州。
3
    3苏州科技城医院，苏州，中国。
4
    4苏州大学附属第一医院江苏省临床免疫研究所，苏州
五
    5苏州大学江苏省临床免疫重点实验室，苏州
6
    6苏州大学附属第一医院江苏省胃肠道肿瘤免疫学重点实验室，苏州

抽象

越来越多的证据表明，CD8 + CD28-调节性T细胞在慢性病毒感染以及肿瘤发生中增加。然而，目前尚不清楚它们在乙型肝炎病毒（HBV）感染中的特征。此外，在影响HBV感染进展或与HBV感染进展相关的方面，尚不清楚该调节免疫亚群是否与CD4 + CD25高调节性T细胞不同。因此，我们调查了他们的动态，并将他们的相关性与HBV感染的慢性和晚期阶段的临床参数进行了比较。数据显示，与健康对照组相比，慢性和晚期CD28 + CD8-和CD4 + CD25高T细胞的频率均增加，而两组病例之间无显着差异。有趣的是，我们发现在慢性期，CD8 + CD28-亚群的频率分别与丙氨酸氨基转氨酶（ALT）和天冬氨酸氨基转移酶（AST）的水平呈负相关，并且与HBV DNA载量无关，而CD4 + CD25high T细胞分别与HBV DNA载量和ALT和AST水平呈正相关。令人惊讶的是，在晚期阶段，CD4 + CD25高T细胞的频率分别与HBV DNA载量和ALT水平呈负相关，而CD8 + CD28-亚群的频率与那些临床参数之间没有显着相关性。因此，我们的研究结果表明，CD28 + CD8-和CD4 + CD25high调节性T细胞可能对调节抗病毒免疫应答和减轻HBV感染不同阶段免疫介导的肝损伤产生明显影响，这代表了HBV感染的潜在预后标志物和治疗靶点。患者在进一步探索详细机制的基础上。
关键词：

CD28 + CD8-调节性T细胞; CD4 + CD25high调节性T细胞;乙型肝炎病毒感染;肝损害

结论：
    30117787
DOI：
    10.1089 / vim.2018.0035

咬牙硬挺

感谢分享！